Beyond conventional antibiotics for the future treatment of methicillin-resistant Staphylococcus aureus infections: two novel alternatives.

Hdl Handle:
http://hdl.handle.net/10147/296027
Title:
Beyond conventional antibiotics for the future treatment of methicillin-resistant Staphylococcus aureus infections: two novel alternatives.
Authors:
Fitzgerald-Hughes, Deirdre; Devocelle, Marc; Humphreys, Hilary
Affiliation:
Department of Clinical Microbiology, Education and Research Centre, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland. dfitzgeraldhughes@rcsi.ie
Citation:
Beyond conventional antibiotics for the future treatment of methicillin-resistant Staphylococcus aureus infections: two novel alternatives. 2012, 65 (3):399-412 FEMS Immunol. Med. Microbiol.
Journal:
FEMS immunology and medical microbiology
Issue Date:
Aug-2012
URI:
http://hdl.handle.net/10147/296027
DOI:
10.1111/j.1574-695X.2012.00954.x
PubMed ID:
22409572
Abstract:
The majority of antibiotics currently used to treat methicillin-resistant Staphylococus aureus (MRSA) infections target bacterial cell wall synthesis or protein synthesis. Only daptomycin has a novel mode of action. Reliance on limited targets for MRSA chemotherapy, has contributed to antimicrobial resistance. Two alternative approaches to the treatment of S. aureus infection, particularly those caused by MRSA, that have alternative mechanisms of action and that address the challenge of antimicrobial resistance are cationic host defence peptides and agents that target S. aureus virulence. Cationic host defence peptides have multiple mechanisms of action and are less likely than conventional agents to select resistant mutants. They are amenable to modifications that improve their stability, effectiveness and selectivity. Some cationic defence peptides such as bactenecin, mucroporin and imcroporin have potent in vitro bactericidal activity against MRSA. Antipathogenic agents also have potential to limit the pathogenesis of S aureus. These are generally small molecules that inhibit virulence targets in S. aureus without killing the bacterium and therefore have limited capacity to promote resistance development. Potential antipathogenic targets include the sortase enzyme system, the accessory gene regulator (agr) and the carotenoid biosynthetic pathway. Inhibitors of these targets have been identified and these may have potential for further development.
Item Type:
Article
Language:
en
MeSH:
Amino Acid Sequence; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Bacterial Proteins; Humans; Metabolic Networks and Pathways; Methicillin-Resistant Staphylococcus aureus; Molecular Sequence Data; Molecular Targeted Therapy; Peptides, Cyclic; Porins; Staphylococcal Infections; Trans-Activators; Virulence; Xanthophylls
ISSN:
1574-695X

Full metadata record

DC FieldValue Language
dc.contributor.authorFitzgerald-Hughes, Deirdreen_GB
dc.contributor.authorDevocelle, Marcen_GB
dc.contributor.authorHumphreys, Hilaryen_GB
dc.date.accessioned2013-07-15T14:49:58Z-
dc.date.available2013-07-15T14:49:58Z-
dc.date.issued2012-08-
dc.identifier.citationBeyond conventional antibiotics for the future treatment of methicillin-resistant Staphylococcus aureus infections: two novel alternatives. 2012, 65 (3):399-412 FEMS Immunol. Med. Microbiol.en_GB
dc.identifier.issn1574-695X-
dc.identifier.pmid22409572-
dc.identifier.doi10.1111/j.1574-695X.2012.00954.x-
dc.identifier.urihttp://hdl.handle.net/10147/296027-
dc.description.abstractThe majority of antibiotics currently used to treat methicillin-resistant Staphylococus aureus (MRSA) infections target bacterial cell wall synthesis or protein synthesis. Only daptomycin has a novel mode of action. Reliance on limited targets for MRSA chemotherapy, has contributed to antimicrobial resistance. Two alternative approaches to the treatment of S. aureus infection, particularly those caused by MRSA, that have alternative mechanisms of action and that address the challenge of antimicrobial resistance are cationic host defence peptides and agents that target S. aureus virulence. Cationic host defence peptides have multiple mechanisms of action and are less likely than conventional agents to select resistant mutants. They are amenable to modifications that improve their stability, effectiveness and selectivity. Some cationic defence peptides such as bactenecin, mucroporin and imcroporin have potent in vitro bactericidal activity against MRSA. Antipathogenic agents also have potential to limit the pathogenesis of S aureus. These are generally small molecules that inhibit virulence targets in S. aureus without killing the bacterium and therefore have limited capacity to promote resistance development. Potential antipathogenic targets include the sortase enzyme system, the accessory gene regulator (agr) and the carotenoid biosynthetic pathway. Inhibitors of these targets have been identified and these may have potential for further development.en_GB
dc.language.isoenen
dc.rightsArchived with thanks to FEMS immunology and medical microbiologyen_GB
dc.subject.meshAmino Acid Sequence-
dc.subject.meshAnti-Bacterial Agents-
dc.subject.meshAntimicrobial Cationic Peptides-
dc.subject.meshBacterial Proteins-
dc.subject.meshHumans-
dc.subject.meshMetabolic Networks and Pathways-
dc.subject.meshMethicillin-Resistant Staphylococcus aureus-
dc.subject.meshMolecular Sequence Data-
dc.subject.meshMolecular Targeted Therapy-
dc.subject.meshPeptides, Cyclic-
dc.subject.meshPorins-
dc.subject.meshStaphylococcal Infections-
dc.subject.meshTrans-Activators-
dc.subject.meshVirulence-
dc.subject.meshXanthophylls-
dc.titleBeyond conventional antibiotics for the future treatment of methicillin-resistant Staphylococcus aureus infections: two novel alternatives.en_GB
dc.typeArticleen
dc.contributor.departmentDepartment of Clinical Microbiology, Education and Research Centre, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland. dfitzgeraldhughes@rcsi.ieen_GB
dc.identifier.journalFEMS immunology and medical microbiologyen_GB
dc.description.fundingOtheren
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.